article thumbnail

Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment

Common Sense for Drug Policy Blog

Receipt of Opioid Use Disorder Treatments Prior to Fatal Overdoses and Comparison to No Treatment "The findings revealed that exposures to MOUD, even if not continued throughout the six-month exposure period was associated with reduced risk of a fatal poisoning compared to non-MOUD forms of treatment and no treatment exposure.

article thumbnail

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

The Pharma Data

FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp. NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that the U.S. BUFFALO, N.Y.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New Drug Miplyffa Approved for Rare Niemann-Pick Disease Type 3

PLOS: DNA Science

FDA approved a treatment for type 3 of the ultra-rare genetic disease September 20. “Despite extensive research efforts, there have not been approved treatments to meet the significant needs of patients. The original approved was in 2003 to treat a type of Gaucher disease. October is Niemann-Pick Awareness Month.

Disease 52
article thumbnail

CAR-NK cells: promising for cancer therapy

Drug Target Review

Only three of the CAR-NK studies were for the treatment of solid tumours. By themselves, the NK cells showed limited efficacy, but anti-tumour efficacy was observed with co-treatment regimens (eg, monoclonal antibodies, haematopoietic stem cell transplants, whole body irradiation) and multiple dosing (tolerated well by patients).

Therapies 118
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

Over the past 25 years, T-cell therapies have gained significant ground in the treatment of cancer. from 2003 to 2006, covering the biotechnology and life-science tools sectors. J Exp Med 198(5):747-755 (2003). Liu Z, Eltoum I-E, Guo B, et al. J Immunol 180(9):6044-6053 (2008). Lamb L, Pereboeva L, Youngblood S, et al.

Therapies 105
article thumbnail

FDA accepts application for self-administered Xolair use

The Pharma Data

It is the only biologic approved which is designed to target and block immunoglobin E (IgE) for the treatment of moderate-to-severe persistent allergic asthma and chronic idiopathic urticaria (CIU). Approximately 460,000 patients in the US have been treated with Xolair since its first approval for allergic asthma back in 2003.

FDA 52
article thumbnail

New understanding of the TMEJ pathway in cancer

Drug Target Review

In 2003, Dr Richard Wood, distinguished Professor at the University of Texas MD Anderson Cancer Center, was a crucial part of the first characterisation of polymerase theta. Polymerase theta TMEJ has been the most elusive DNA repair pathway. Polymerase delta also aids polymerase theta in finishing synthesis.

DNA 59